Work

Clinical activity and safety of PF-06463922 from a dose escalation study in patients with advanced ALK+ or ROS1+ NSCLC.

Year: 2015

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2015.33.15_suppl.8018

Authors: Alice Tsang Shaw, Todd Michael Bauer, Enriqueta Felip, Benjamin Besse, Leonard Philip James, Jill S. Clancy, Ganesh Mugundu, Jean-Francois Martini, Antonello Abbattista, Benjamin J. Solomon

Institutions: Massachusetts General Hospital, Sarah Cannon, Tennessee Oncology, Vall d'Hebron Hospital Universitari, Institut Gustave Roussy, Pfizer (United States), Pfizer (Italy), Peter MacCallum Cancer Centre

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2525528564

Cites:

Cited by: 42

Related to: 10